FLEE - ETF AI Analysis
Top Page
Franklin FTSE Europe ETF (FLEE)
FLEE, the Franklin FTSE Europe ETF, earns a solid overall rating thanks to several high-quality European blue chips like Novartis, HSBC, and AstraZeneca, which bring strong financial performance, positive earnings outlooks, and generally supportive technical trends to the portfolio. At the same time, holdings such as SAP, with bearish momentum and valuation concerns, and names facing overvaluation or profitability challenges slightly weigh on the fund’s appeal. The main risk factor is its concentrated exposure to European markets and sectors, meaning regional economic or regulatory issues could impact many holdings at once.
FLEE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 99.74M
- Region
- Europe
- Expense Ratio
- 0.09%
- Beta
- 0.72
- Issuer
- Franklin
- Inception Date
- Nov 02, 2017
- Dividend Yield
- 3.21%
- Asset Class
- Equity
- Index Tracked
- FTSE Developed Europe RIC Capped Index
FLEE Summary
Franklin FTSE Europe ETF (FLEE) is a fund that aims to track the FTSE Developed Europe Index, giving you broad exposure to many companies across major European countries like the UK, Germany, France, and Switzerland. It holds well-known names such as Nestlé and Shell, along with banks, healthcare firms, and industrial companies, so you’re not relying on just one sector. Someone might invest in FLEE to add international diversification and long-term growth potential to a portfolio. A key risk is that European stock markets can rise and fall, so the value of this ETF can go up and down with the market.
How much will it cost me?
This ETF has an expense ratio of 0.09%, which means you’ll pay about $0.90 per year for every $1,000 you invest. That’s lower than the average ETF because it’s passively managed and simply tracks a broad European market index instead of paying managers to pick individual stocks.
What would affect this ETF?
This Europe-focused ETF could benefit if European economies grow steadily, interest rates stabilize or fall, and major holdings like ASML, Nestlé, and leading healthcare and financial companies continue to perform well, supporting broad market gains. On the other hand, slower economic growth in Europe, banking sector stress, energy price shocks, or new regulations affecting big European firms could weigh on returns and increase volatility for investors.
FLEE Top 10 Holdings
This Europe-focused ETF leans heavily on a mix of health care, energy, and financial giants to drive returns. ASML has been a powerful long‑term engine, though its recent momentum looks a bit mixed. Roche and Novartis are rising steadily, giving the fund a solid defensive backbone from Switzerland’s pharma heavyweights. On the energy side, Shell and TotalEnergies have been climbing, helping offset softer stretches from names like Nestlé and AstraZeneca, which are losing some steam. Overall, it’s a developed Europe story, with broad country exposure rather than a single‑market bet.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 4.27% | $4.22M | EUR 539.67B | 50.70% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:SHEL | Shell (UK) | 2.21% | $2.19M | GBP 229.30B | 40.01% | 73Outperform |
 GB:HSBA | HSBC Holdings | 2.06% | $2.03M | GBP 218.81B | 19.37% | 80Outperform |
 CH:NOVN | Novartis AG | 2.12% | $2.10M | CHF 244.89B | 35.30% | 80Outperform |
 CH:NESN | Nestlé SA | 1.86% | $1.83M | CHF 217.87B | 9.36% | 71Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 DE:SAP | SAP SE | 1.62% | $1.60M | EUR 246.65B | -6.46% | 66Neutral |
 DE:SIE | Siemens | 1.51% | $1.49M | EUR 202.50B | 7.55% | 74Outperform |
 FR:TTE | TotalEnergies SE | 1.34% | $1.32M | EUR 190.70B | 59.27% | 78Outperform |
FLEE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FLEE, the sentiment is Positive. The current price of 38.08 is above the 20-day moving average (MA) of 37.77, below the 50-day MA of 38.58, and above the 200-day MA of 37.98, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 50.36 is Neutral, neither overbought nor oversold. The STOCH value of 74.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLEE.
FLEE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FLEE | $38.08 | $41.00(7.67% Upside) | $99.74M | 0.09% | 64Neutral |
 FLEU | $33.84 | $41.68(23.15% Upside) | $68.44M | 0.09% | 62Neutral |
 DBEZ | $60.87 | $74.64(22.62% Upside) | $67.94M | 0.45% | 61Neutral |
 EUDG | $38.12 | $44.76(17.43% Upside) | $66.98M | 0.58% | 64Neutral |
 PTEU | $31.58 | $38.82(22.95% Upside) | $33.80M | 0.65% | 62Neutral |
 XEML | $25.11 | $28.75(14.49% Upside) | $4.98M | 0.35% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FLEE | Franklin FTSE Europe ETF | 38.08 | 4.13 | 12.17% | |
| FLEU | Franklin FTSE Eurozone ETF | 33.84 | 2.53 | 8.09% | |
| DBEZ | Xtrackers MSCI Eurozone Hedged Equity ETF | 60.87 | 7.11 | 13.22% | |
| EUDG | WisdomTree Europe Quality Dividend Growth Fund | 38.12 | 3.60 | 10.44% | |
| PTEU | Pacer Trendpilot European Index ETF | 31.57 | 2.07 | 7.03% | |
| XEML | Xtrackers Europe Market Leaders ETF | 25.11 | 0.34 | 1.36% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.